Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s Zelboraf

Jun 03 2013

• By Emily Hayes

Related Content

Glaxo’s Emerging BRAF/MEK Melanoma Combo Threatens Roche’s <em>Zelboraf</em>

Nov 26 2012

Questioning <em>Stivarga</em>’s Cost-Effectiveness In Colon Cancer

Dec 03 2012

Over A Decade In The Making, MEK Inhibitors Break Through In Melanoma

Jun 20 2012

Many New Oncology Drugs In 2012, With Prices That Test The Limits

Feb 26 2013

Related Companies

GSK plc

Roche Holding AG

Bristol Myers Squibb Company

Additional Topics

Clinical Trials Regulation Approvals Drug Approval Standards

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window